Investing.com - BMO Capital已将安进 (Amgen) (NASDAQ: AMGN )的目标价从346.00美元下调至335.00美元，同时维持"优于大市"评级。根据 InvestingPro 的数据，这家知名生物技术公司在过去十二个月实现了15.56%的收入增长，并保持"良好"的财务健康评分，目前交易价格略低于其公允价值。

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...

This year, drug companies have been living under a cloud of uncertainty created by the Trump administration. Threats of tough ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

The drugmaker's dividend streak is impressive, and the stock is trading at reasonable levels. 10 stocks we like better than Amgen › Generating passive income is great for investors, and holding ...

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical ...